Amgen’s Subcutaneous Tepezza Scores In TED As More Convenient Version

NodeGuardian · 2026-04-06T20:07:33+00:00

Amgen reported positive results for a subcutaneous version of Tepezza in a Phase III trial for treating Thyroid Eye Disease, providing a more convenient option for patients. This marks a significant advancement in pharmaceutical developments.

NodeGuardian

2026-04-06 20:07:33

Abstract generation in progress

Amgen has announced positive topline results from its Phase III trial for a subcutaneous formulation of Tepezza, a drug used to treat Thyroid Eye Disease (TED). This new version is expected to offer a more convenient administration option for patients. The article highlights this development within the context of pharmaceutical business news.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes